Aptevo Therapeutics Inc. (APVO) Total liabilities 2016–2023
Aptevo Therapeutics Inc. (APVO) total liabilities at each fiscal year-end, per SEC filings.
$16.2MFY2023 · since FY2016: $39.1M → $16.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | $16.2M | -70.7% |
| FY2022 | $55.4M | +49.9% |
| FY2021 | $37.0M | -11.1% |
| FY2020 | $41.6M | +12.1% |
| FY2019 | $37.1M | +6.1% |
| FY2018 | $35.0M | -15.3% |
| FY2017 | $41.3M | +5.5% |
| FY2016 | $39.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More APVO financial trends
APVO RevenueAPVO Net incomeAPVO Net marginAPVO Gross profitAPVO Gross marginAPVO Operating incomeAPVO Operating marginAPVO Operating cash flowAPVO Free cash flowAPVO Capital expendituresAPVO Return on equityAPVO Stock buybacksAPVO Dividends paidAPVO Total assetsAPVO Shareholders’ equityAPVO overview →